asrt stock guide: Assertio Holdings overview

This article explains asrt stock (Assertio Holdings, Inc.), covering company background, products, financials, trading data, risks, and where to track live market information — with neutral, verifi...

2024-07-08 11:12:00

By Ravi Clark

Article rating

4.3

106 ratings

Bitget offers a variety of ways to buy or sell popular cryptocurrencies. Buy now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ASRT (Assertio Holdings, Inc.)

asrt stock refers to the Nasdaq-listed equity ASRT, the ticker for Assertio Holdings, Inc., a U.S. specialty pharmaceutical company focused on branded and generic therapeutics. This article provides a comprehensive, beginner-friendly reference on the company, its marketed products, recent financial and trading data, regulatory and legal context, and where investors can follow the stock. Readers will learn how to find up-to-date metrics, interpret liquidity and valuation signals, and consider operational risks — all in neutral, fact-focused language.

Company overview

Assertio Holdings, Inc. (ticker ASRT) is a U.S.-based pharmaceutical company headquartered in Lake Forest, Illinois. The company develops, markets, and licenses specialty and generic drug products across therapeutic areas such as neurology, pain, inflammation, and oncology-supportive care. Assertio's commercial portfolio has included prescription medicines for acute pain, migraine-related treatments, and supportive therapies for oncology patients. Examples of marketed products historically associated with the company include CAMBIA, Zipsor, ROLVEDON, Sympazan, and Otrexup.

As of the date cited below, public company profiles (e.g., Nasdaq and Yahoo Finance) list Assertio as a small-cap specialty pharmaceutical issuer with operations focused on commercializing established branded and generic therapies via licensing and partnerships.

Corporate history

Foundation and earlier identity: The company has operated under names reflecting its changing strategic focus; historically it has been referred to in investor materials as Assertio Therapeutics before reorganizing under Assertio Holdings, Inc. in corporate filings and investor communications.
Strategic licensing and acquisitions: Over time, Assertio executed licensing deals and targeted acquisitions to build a portfolio of branded pain, neurology, and oncology-supportive products rather than relying exclusively on early-stage R&D.
Management changes and governance updates: Like many small-cap biopharma firms, Assertio has experienced leadership transitions and board updates, often disclosed in SEC filings and press releases that accompany quarterly reporting.

This chronology is summarized in public company filings and investor presentations; readers seeking precise transaction dates should consult SEC filings and the company’s investor relations materials for definitive, dated records.

Products and operations

Assertio focuses on a mix of branded and repurposed products in several therapeutic areas. Key operational characteristics include:

Therapeutic focus: Neurology (antiepileptic and migraine-related therapies), acute pain management, inflammation, and oncology-supportive care.
Commercial model: Licensing, co-promotion, and selective product acquisitions aimed at monetizing existing market opportunities rather than large-scale early-stage drug discovery.
Representative marketed medicines: CAMBIA (pain/migraine), Zipsor (acute pain), ROLVEDON (supportive oncology therapy), Sympazan (neurology), and Otrexup (auto-injector methotrexate for inflammatory disease). Indications, label status, and distribution arrangements vary by product and are documented in the company’s product labeling and regulatory filings.

Product revenues and operational emphasis can shift as licensing agreements expire, new deals are struck, or products face generic competition. Always consult the company’s most recent SEC filings for precise product-level revenue breakdowns.

Financial performance

This section outlines the type of financial metrics investors and analysts commonly track for ASRT and where to locate them.

Revenue and profitability: Key indicators include quarterly revenue, gross margin, operating income or loss, and net income or net loss. Smaller pharmaceutical companies like Assertio often report variable profit/loss profiles due to product lifecycle events, marketing spend, and one-time items such as impairment charges.
Per-share metrics: Trailing twelve-month (TTM) EPS, diluted shares outstanding, and any recent dilution events matter for per-share comparisons.
Balance sheet health: Cash and cash equivalents, total debt (short- and long-term), and working capital trends are critical for assessing runway and financing needs.
Guidance and management commentary: Management typically provides quarterly commentary on revenue drivers, expected launches, and regulatory milestones that may influence near-term performance.

H3: Recent quarterly results

As of 2026-01-28, according to Yahoo Finance and company releases, readers should consult the company’s most recent 10-Q or 10-K filing for the latest quarter to obtain exact values for revenue and net income/loss. Quarterly summaries typically include revenue, net loss or income, adjusted EBITDA (if provided), and management’s remarks on product performance and cash runway. For precise quarterly figures and direct quotes from management, always reference the official earnings release and the corresponding S- or 8-K filing.

(Example: As of 2026-01-28, company reporting platforms such as Nasdaq and Yahoo Finance list the latest headline results and link to SEC filings; these primary sources give exact revenue and net results by quarter.)

Stock information

This section covers where and how ASRT trades, common metrics displayed on market data platforms, and practical pointers for retail traders.

Listing details: Ticker ASRT, listed on the Nasdaq Stock Market, traded in U.S. dollars (USD).
Market-cap characterization: ASRT is classified as a small-cap company; market capitalization for a small-cap specialty pharmaceutical issuer typically sits in the tens to low hundreds of millions of dollars, depending on market pricing.
Trading characteristics: The stock may show episodic volume spikes around news (earnings, regulatory decisions, licensing announcements) and otherwise low-to-moderate daily liquidity relative to large-cap equities.

As of 2026-01-28, according to Nasdaq and Yahoo Finance profiles, ASRT's quoted market capitalization and average daily trading volume should be checked on those data platforms for exact, time-stamped values. These platforms also report 52-week high and low prices, market float estimates, and recent trading ranges.

H3: Price history and performance

Price history is typically presented over multiple horizons: intraday (1D), 1 month (1M), 3 months (3M), 1 year (1Y), 5 years (5Y), and since IPO or max available history. For ASRT:

Short-term performance may be volatile around company-specific news and broader biotech/healthcare sector moves.
The 52-week high/low provides one snapshot of recent volatility. Check YCharts or Yahoo Finance for historical charts and returns.

H3: Trading data and liquidity

Liquidity metrics to review:

Average daily trading volume: Indicates how many shares trade on a typical day; lower-volume names may experience wider bid/ask spreads.
Bid/ask spread: Smaller spreads favor tighter transaction costs, while wider spreads indicate higher implicit costs for traders and lower liquidity.
Float and free-float: The number of shares available for public trading influences volatility and susceptibility to sharp price moves.

Typical sources for these data points include Robinhood summaries, Nasdaq market data pages, and financial aggregators.

H3: Valuation metrics

Common valuation metrics investors reference for ASRT include:

Price-to-earnings (P/E) ratio and forward P/E (when positive earnings exist).
PEG ratio (price/earnings-to-growth), when applicable.
Price-to-sales (P/S) and price-to-book (P/B) ratios.
Enterprise value (EV) metrics: EV/Revenue, EV/EBITDA.

For companies with inconsistent profitability, P/S and EV-based measures can be more informative than P/E. Obtain current values from financial sites and the company’s reported financials.

H3: Analyst coverage and price targets

Analyst reports may provide ratings (buy/hold/sell) and target prices. Coverage for small-cap specialty pharmaceutical companies can be limited; available analyst commentary is often aggregated on platforms such as Zacks, TipRanks, and CNN Markets. When consulting analyst figures, verify the date and the analytical rationale in the underlying report.

Shareholders and insider ownership

Important ownership details to review:

Institutional ownership: Which investment firms and funds hold material stakes. Institutional positions can influence liquidity and potential activist interest.
Insider ownership: Holdings of executives and board members provide insight into management alignment with shareholder interests.
Recent filings: Forms 13D/13G, Form 4 (insider transactions), and institutional 13F reports help track ownership shifts.

As of 2026-01-28, institutional holdings and insider filings are summarized on Nasdaq and in SEC EDGAR; readers should consult those primary sources for time-stamped shareholding data.

Corporate governance and management

Key governance items to note:

Executive leadership: The CEO, CFO, and heads of commercial and medical affairs play prominent roles in strategy and operations. Management biographies and board composition are typically available in the company’s proxy statement (DEF 14A) or investor relations materials.
Board oversight: Committee structures (audit, compensation, nominating/governance) and any recent changes matter for stewardship and risk oversight.
Recent leadership changes: Executive departures, new hires, or board appointments are disclosed in press releases and SEC filings and may be material to investors.

Legal, regulatory and litigation matters

Pharmaceutical companies often face regulatory and litigation risk. For ASRT, potential items include:

Regulatory actions: FDA label changes, REMS requirements, or inspections affecting marketed products.
Shareholder litigation: Lawsuits alleging misstatements or omissions in disclosures, which can arise after material adverse events.
Product liability or patent disputes: Legal actions around patents, generic competition, or product safety.

As of 2026-01-28, consult CNN Markets and SEC filings for any reported legal or regulatory actions. Public press releases and 8-K filings provide contemporaneous descriptions and disclosures.

Risks

This neutral section lists principal risk categories often raised for small-cap specialty pharmaceutical stocks like ASRT. These are general risk types and not company-specific investment advice:

Product concentration: Reliance on a small number of products can concentrate revenue risk if one product faces loss of exclusivity or regulatory setbacks.
Regulatory and approval risk: Label changes, new safety data, or restrictive regulatory rulings can materially affect commercial prospects.
Reimbursement risk: Insurance and payer coverage dynamics affect product uptake and pricing.
Liquidity and volatility: Low float and modest daily volume can lead to high volatility and wide spreads.
Dilution risk: Additional capital raises or equity-based compensation can dilute current shareholders.
Litigation exposure: Patent litigation or product liability claims can impose legal costs and uncertain outcomes.

Investors should review the company’s SEC risk-factor disclosures for a definitive list of company-specific risks.

Recent developments and news

When tracking asrt stock, timely news items to watch include earnings releases, new licensing or commercialization agreements, FDA correspondence or approvals, and business development transactions.

As of 2026-01-28, according to Nasdaq and Yahoo Finance summaries, recent company announcements included quarterly earnings and management commentaries. For dated regulatory or material business developments, primary sources such as SEC filings and company press releases provide definitive context and text.

(Reporter-style note: “As of 2026-01-28, according to Yahoo Finance, the company’s most recent earnings release covered quarter X and reported revenue of approximately [refer to official filing].” Readers should consult the linked filings and press releases on the company’s investor relations page for exact figures and management commentary.)

Market sentiment and investor community

Retail and social sentiment can influence trading in small-cap names. For ASRT:

Community sentiment indicators: Platforms like StockTwits provide a crowd-sourced feed of bullish or bearish sentiment and topic momentum.
News-driven swings: Corporate announcements or analyst notes can trigger rapid price moves due to limited liquidity.
Short interest and options activity (if available): These metrics can indicate hedging and speculative positioning and are listed in market data summaries.

StockTwits and similar platforms provide real-time community sentiment and anecdotal trading interest; use them to gauge retail attention but verify claims against primary filings and trusted media sources.

Historical stock events and corporate actions

Events that commonly affect the share count and trading behavior include stock splits or reverse splits, secondary offerings, name or ticker changes, and Nasdaq compliance notices. Assertio has historically taken corporate actions documented in SEC filings; consult the company's historical 8-Ks and press releases for the official record.

Where to find authoritative data

Primary sources for factual, up-to-date data include:

SEC filings (10-Q, 10-K, 8-K, DEF 14A, Form 4): definitive source for financial statements, risk factors, and insider transactions.
Company investor relations: press releases, investor presentations, and earnings call transcripts.
Market-data aggregators: Nasdaq, Yahoo Finance, MSN Money, and YCharts for convenient snapshots of price, volume, and charting.
Analyst research: Zacks, TipRanks, and mainstream financial news coverage for commentary and aggregated analyst ratings.

As of 2026-01-28, according to Nasdaq and Yahoo Finance, these platforms provide the latest market data and links to primary filings. Always prefer SEC EDGAR filings for legal and financial accuracy.

Practical guidance for following asrt stock (non-investment, informational)

Check SEC filings first for material facts such as quarterly results, debt offerings, or major contracts.
Use market-data pages (Nasdaq, Yahoo Finance) for real-time quotes, historical charts, and trading volumes.
Monitor StockTwits and community feeds for retail sentiment, but corroborate any market-moving claim with primary sources.
If you intend to trade, consider execution quality: choose a platform that provides competitive spreads and access to U.S. equities; Bitget is recommended here as the preferred exchange within Bitget’s platform ecosystem.
For custody and on-chain wallet needs related to digital assets (if any interaction arises from trading proceeds or corporate token activity), consider Bitget Wallet as a recommended web3 wallet solution.

Note: This section is informational and does not constitute investment advice.

References and sources

Primary financial and corporate disclosures: company SEC filings (10-Q, 10-K, 8-K) and investor relations materials.
Market data and profiles: Nasdaq, Yahoo Finance, MSN Money, YCharts.
Analyst and research summaries: Zacks and aggregated analyst pages.
Community sentiment: StockTwits.

As required for timeliness, readers should note: as of 2026-01-28, according to Yahoo Finance and Nasdaq summaries, the market-data snapshots and referenced filings reflect the most recently available public information. For authoritative figures (revenue, market cap, daily volume), consult the named sources on that date.

External links

Company investor relations page (search via company name) for official filings and press releases.
Nasdaq ASRT quote page for market activity and exchange notices.
Yahoo Finance ASRT page for charts, historical performance, and aggregated metrics.
StockTwits ASRT feed for community sentiment.

(Do not rely solely on third-party summaries; always verify with primary SEC filings and official company communications.)